Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
B.1.160.19NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.160.19NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.160.19NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
B.1.160.12NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.160.12NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.160.12NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
AT.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
AT.1NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
AT.1NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
B.1.619.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.619.1NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.619.1NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
P.1.12.1 (Gamma)NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
P.1.12.1 (Gamma)NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
P.1.12.1 (Gamma)NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
B.1.160.22NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.160.22NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.160.22NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
AZ.2.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
AZ.2.1NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
AZ.2.1NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
B.1.260NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.260NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.260NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
B.1.456NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.456NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.456NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
B.1.160.16NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.160.16NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.160.16NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
AY.4.16 (Delta)NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
AY.4.16 (Delta)NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
AY.4.16 (Delta)NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
BA.1.22NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BA.1.22NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BA.1.22NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
B.1.177.70NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.177.70NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.177.70NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
B.1.177.42NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.177.42NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.177.42NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
B.1.1.428NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.1.428NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.1.428NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
B.1.1.374NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.1.374NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.1.374NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
AY.63 (Delta)NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
AY.63 (Delta)NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used